NewGen Technologies

NewGen Therapeutics is a private biotechnology company focused on the discovery and development of novel small molecule therapeutics for the treatment of cancer. The company's research efforts primarily target key signaling pathways involved in tumor growth and survival, specifically focusing on dual inhibitors of the PI3K/mTOR pathway and selective inhibitors of CDK4/6. NewGen's lead programs aim to address resistance mechanisms in various solid tumors, including breast and lung cancers. By leveraging its expertise in medicinal chemistry and oncology biology, the company seeks to develop next-generation kinase inhibitors with improved potency and safety profiles. NewGen Therapeutics operates primarily out of the San Francisco Bay Area, positioning itself within a major hub for oncology innovation.